Thursday, October 30, 2014 10:05:46 AM
Also, peer reviewed articles are typically submitted after phase 2b trials have been completed. There is limited interest in safety alone among those in the biotechnology sector, they want to know if the drug/mechanism works, is it effective, and is it safe. The primary goal of 1b/2a studies, which ONCS is currently working on, are safety and dosing, not efficacy.
I know you are new to investing so I am trying to keep it simple for you. But in short, you first have to complete a study before submitting the data for peer review and data for safety trial is not typically reported. Like PVCT or CYTK, most companies wait until after the completion of a P2B to submit data for a peer review.
Hope that helps and keep up the hard work. Happy trading to you.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM